A Randomized And Placebo-Controlled Phase II Trial Targeting Dominant-Negative Missense Mutant P53 By Atorvastatin For Reducing The Risk Of Longstanding Ulcerative Colitis-Associated Cancer

Brief Summary

Type:
Gastrointestinal - Other

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04767984

Study #:
STUDY00149590

Start Date:
Apr 16, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04767984

View Complete Trial Details & Eligibility at ClinicalTrials.gov